Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2018
At a glance
- Drugs Evacetrapib (Primary)
- Indications Atherosclerosis; Cardiovascular disorders; Dyslipidaemias
- Focus Pharmacokinetics
- 09 Feb 2016 Results of this other trial (see profile 231542) published in the European Journal of Clinical Pharmacology
- 10 Oct 2013 Planned End Date changed from 1 Dec 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov record.
- 01 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.